Machine learning alerts to reduce central line bloodstream infections

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, open-label, multi-center, cluster-randomized trial across 20 Providence hospitals testing whether a machine learning model that predicts possible CLABSI, when provided to Infection Preventionists with a standardized workflow, reduces CLABSI rates compared with routine practice. The intervention delivers just-in-time risk alerts and prompts IP-led clinical education, reminders of best-practice central-line care, and targeted actions such as line removal within 48 hours of an alert. Secondary outcomes include line removal within 48 hours, rates of positive blood cultures, frequency of IP interventions, and safety events (for example, pneumothorax and hemorrhage). The trial uses electronic health record data for real-time prediction and tracks both process metrics and clinical outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The top twenty Providence St. Joseph Health Hospitals by CLABSI burden.

Exclusion Criteria:

* Less than 18 years of age

Where it's running

• Providence Alaska Medical Center
  Anchorage, Alaska, United States Recruiting
• St. Mary Medical Center
  Apple Valley, California, United States Recruiting
• Providence Saint Joseph Medical Center
  Burbank, California, United States Recruiting
• St. Jude Medical Center
  Fullerton, California, United States Recruiting
• Providence Holy Cross Medical Center
  Mission Hills, California, United States Recruiting
• Mission Hospital
  Mission Viejo, California, United States Recruiting

Study contacts

• Principal investigator: Chris Dale, MD, MPH — Swedish Medical Center
• Study coordinator: Chris Dale, MD, MPH
• Email: christopher.dale@swedish.org
• Phone: 425-747-5822

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing DEFENCATH® to Heparin for Preventing Infections in Patients on Total Parenteral Nutrition

  This study is testing whether a new solution called DEFENCATH® can better prevent infections in adults who are getting nutrition through a central line compared to the standard treatment with heparin.

  Recruiting at 22 sites Phase 3 CorMedix Therapeutics · Los Angeles, California and 23 other locations · NCT06822426

• Early removal of chest tubes after surgery for spontaneous pneumothorax

  This study tests if taking out chest tubes a day earlier after surgery for a collapsed lung helps patients feel better and leave the hospital sooner without increasing the chance of problems.

  Recruiting Swedish Medical Center · Seattle, Washington · NCT06411431

• Pain control methods for patients undergoing esophagectomy

  This study is testing three different ways to manage pain for patients having minimally invasive esophagectomies to see which one works best.

  Recruiting Phase 1/2 Swedish Medical Center · Seattle, Washington · NCT05906134

• Personalized drug screening for glioblastoma treatment

  This study is testing if personalized combinations of FDA-approved drugs can improve treatment for people with newly diagnosed glioblastoma when used with standard therapy.

  Recruiting Early Phase 1 Swedish Medical Center · Seattle, Washington · NCT05380349

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.